Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Weak
Growth
Earnings
Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.8.9389.1992
Address
QQ Block, Nedlands 6 Verdun Street QEII Medical Centre Perth, Western Australia (WA) 6009
Description
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.35 - 1.12
Trade Value (12mth)
AU$35,417.00
1 week
-3.95%
1 month
-18.89%
YTD
-53.5%
1 year
-64.56%
All time high
1.48
EPS 3 yr Growth
80.40%
EBITDA Margin
-916.60%
Operating Cashflow
-$6m
Free Cash Flow Return
-62.00%
ROIC
-70.70%
Interest Coverage
-352.80
Quick Ratio
10.10
Shares on Issue (Fully Dilluted)
131m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.47
Date | Announcements |
---|---|
05 May 25 |
Share Purchase Plan Offer Booklet
×
Share Purchase Plan Offer Booklet |
02 May 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
02 May 25 |
Correction - Notice of Extraordinary General Meeting/Proxy
×
Correction - Notice of Extraordinary General Meeting/Proxy |
29 April 25 |
Application for quotation of securities - PIQ
×
Application for quotation of securities - PIQ |
29 April 25 |
Notification regarding unquoted securities - PIQ
×
Notification regarding unquoted securities - PIQ |
29 April 25 |
Notice Under Section 708A
×
Notice Under Section 708A |
28 April 25 |
Options Prospectus
×
Options Prospectus |
24 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
22 April 25 |
$4.5m placement to launch Promarker diagnostics
×
$4.5m placement to launch Promarker diagnostics |
22 April 25 |
Proposed issue of securities - PIQ
×
Proposed issue of securities - PIQ |
22 April 25 |
Proposed issue of securities - PIQ
×
Proposed issue of securities - PIQ |
22 April 25 |
Proposed issue of securities - PIQ
×
Proposed issue of securities - PIQ |
22 April 25 |
Proposed issue of securities - PIQ
×
Proposed issue of securities - PIQ |
16 April 25 |
Pause in Trading
×
Pause in Trading |
16 April 25 |
Trading Halt
×
Trading Halt |
10 April 25 |
Investor Presentation - JMM Biotech Forum
×
Investor Presentation - JMM Biotech Forum |
08 April 25 |
Investor Presentation Morgan Stanley Alpha ex-100 Conference
×
Investor Presentation Morgan Stanley Alpha ex-100 Conference |
07 April 25 |
Proteomics appoints Clinical Advisory Board for PromarkerEso
×
Proteomics appoints Clinical Advisory Board for PromarkerEso |
28 March 25 |
Australian patent granted for OxiDx oxidative stress test
×
Australian patent granted for OxiDx oxidative stress test |
20 March 25 |
Investor Presentation - Broker Meets Biotech
×
Investor Presentation - Broker Meets Biotech |
17 March 25 |
Response to ASX Aware Query
×
Response to ASX Aware Query |
13 March 25 |
PromarkerD predictive test for DKD launched in Australia
×
PromarkerD predictive test for DKD launched in Australia |
11 March 25 |
PromarkerD outperforms conventional tests--results published
×
PromarkerD outperforms conventional tests--results published |
28 February 25 |
Proteomics opens CLIA certified reference laboratory in USA
×
Proteomics opens CLIA certified reference laboratory in USA |
26 February 25 |
Interim Financial Report and Appendix 4D
×
Interim Financial Report and Appendix 4D |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.